Host-response biomarkers for precision tuberculosis: from immune transcriptomic signatures to clinical risk stratification
Frontiers in Cell and Developmental Biology · 24.08.2026 · 14
DOI: 10.3389/fcell.2026.1916291 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 24.08.2026. Verfasst von Nan Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tuberculosis, Affiliated Hospital of Hebei University, Baoding, Hebei, China. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tuberculosis (TB) remains a major infectious cause of morbidity and mortality, while current diagnostic and treatment-monitoring pathways remain largely pathogen-centered. Microbiological tests are indispensable for confirming TB and detecting drug resistance, but they do not directly measure host inflammatory activity, disease-stage heterogeneity, risk of progression, biological response to therapy, or recurrence after treatment completion. Host-response biomarkers, particularly blood transcriptomic signatures, provide a complementary route toward precision TB medicine. Recent multicenter validation studies, household-contact cohorts, treatment-monitoring analyses, cell-free RNA profiling, single-cell studies, and recurrence cohorts have refined the translational evidence base for immune transcriptomic biomarkers. Across studies, active and progressive TB is characterized by interferon-inducible transcription, inflammatory myeloid remodeling, neutrophil and monocyte activation, antigen-specific T-cell activation, and partial normalization during effective therapy. These signals can support clinically relevant use cases, including sputum-independent triage of symptomatic patients, short-term prediction of progression among exposed contacts, identification of subclinical or incipient disease biology, treatment-response monitoring, and post-treatment recurrence detection. However, implementation is constrained by imperfect specificity against non-TB inflammation, heterogeneity across HIV, diabetes, pediatric, extrapulmonary and geographically diverse populations, assay standardization requirements, and limited interventional evidence. This Mini Review synthesizes recent evidence and proposes a focused translational framework linking immune transcriptomic mechanisms to actionable clinical risk stratification in TB.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Tuberculosis, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
- Department of Integrated Traditional Chinese and Western Medicine, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
- Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
- Department of Infectious Diseases, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
- Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
- Department of Respiratory Medicine, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Zitieren
APA
Yan, N., Wang, Z., Dong, S., Wang, S., Sun, Q., & Luan, J. (2026). Host-response biomarkers for precision tuberculosis: from immune transcriptomic signatures to clinical risk stratification. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1916291
Vancouver
Yan N, Wang Z, Dong S, Wang S, Sun Q, Luan J. Host-response biomarkers for precision tuberculosis: from immune transcriptomic signatures to clinical risk stratification. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1916291
BibTeX
@article{Yan2026,
author = {Yan, Nan and Wang, Zhen and Dong, Shilei and Wang, Si and Sun, Qinlong and Luan, Jiusong},
title = {Host-response biomarkers for precision tuberculosis: from immune transcriptomic signatures to clinical risk stratification},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1916291}
}
EUVIMED